EP3765853C0 - Verfahren zur überwachung der behandlungsreaktion und des krankheitsverlaufs in subjekten unter verwendung zirkulierender zellen - Google Patents

Verfahren zur überwachung der behandlungsreaktion und des krankheitsverlaufs in subjekten unter verwendung zirkulierender zellen

Info

Publication number
EP3765853C0
EP3765853C0 EP19713958.7A EP19713958A EP3765853C0 EP 3765853 C0 EP3765853 C0 EP 3765853C0 EP 19713958 A EP19713958 A EP 19713958A EP 3765853 C0 EP3765853 C0 EP 3765853C0
Authority
EP
European Patent Office
Prior art keywords
subjects
methods
treatment response
circulating cells
monitoring treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19713958.7A
Other languages
English (en)
French (fr)
Other versions
EP3765853B1 (de
EP3765853A1 (de
Inventor
Daniel Adams
Cha-Mei Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creatv Microtech Inc
Original Assignee
Creatv Microtech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creatv Microtech Inc filed Critical Creatv Microtech Inc
Publication of EP3765853A1 publication Critical patent/EP3765853A1/de
Application granted granted Critical
Publication of EP3765853B1 publication Critical patent/EP3765853B1/de
Publication of EP3765853C0 publication Critical patent/EP3765853C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19713958.7A 2018-03-13 2019-03-13 Verfahren zur überwachung der behandlungsreaktion und des krankheitsverlaufs in subjekten unter verwendung zirkulierender zellen Active EP3765853B1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862642318P 2018-03-13 2018-03-13
US201862658122P 2018-04-16 2018-04-16
US201862747796P 2018-10-19 2018-10-19
US201862768561P 2018-11-16 2018-11-16
US201962794580P 2019-01-19 2019-01-19
PCT/US2019/022050 WO2019178226A1 (en) 2018-03-13 2019-03-13 Methods for monitoring treatment response and disease progression in subjects using circulating cells

Publications (3)

Publication Number Publication Date
EP3765853A1 EP3765853A1 (de) 2021-01-20
EP3765853B1 EP3765853B1 (de) 2024-05-01
EP3765853C0 true EP3765853C0 (de) 2024-05-01

Family

ID=65952109

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19713958.7A Active EP3765853B1 (de) 2018-03-13 2019-03-13 Verfahren zur überwachung der behandlungsreaktion und des krankheitsverlaufs in subjekten unter verwendung zirkulierender zellen

Country Status (9)

Country Link
US (1) US20210041445A1 (de)
EP (1) EP3765853B1 (de)
JP (2) JP7449640B2 (de)
KR (1) KR102834526B1 (de)
CN (1) CN112074742A (de)
AU (1) AU2019235771B2 (de)
CA (1) CA3093053A1 (de)
ES (1) ES2980135T3 (de)
WO (1) WO2019178226A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021201041B2 (en) 2020-02-19 2023-03-16 Lg Electronics Inc. Laundry treating apparatus
EP4374168A4 (de) * 2021-07-21 2025-04-16 Creatv Microtech, Inc. Verfahren zur vorhersage und/oder überwachung der krebsbehandlungsreaktion unter verwendung von veränderungen in zirkulierenden krebsassoziierten makrophagenartigen zellen (campls)
WO2023159427A1 (zh) * 2022-02-24 2023-08-31 青岛华赛伯曼医学细胞生物有限公司 共表达CD45和EpCAM的细胞群的检测和分离方法及其用途
GB2617409B (en) * 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
KR20250053141A (ko) * 2022-08-18 2025-04-21 크리에티브이 마이크로테크, 인크. 순환 기질세포의 세포외 소포 및 미세핵의 임상 결과 예측을 위한 범암적 바이오마커로서의 용도
EP4720669A1 (de) * 2023-06-02 2026-04-08 Creatv Microtech, Inc. Verfahren zur vorhersage des progressionsfreien überlebens und des gesamtüberlebens bei patienten mit krebs unter verwendung von tumormakrophagenhybridzellen
WO2025170175A1 (ko) * 2024-02-06 2025-08-14 아주대학교 산학협력단 위암 복막 재발 위험도 예측용 바이오마커

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1612936A (zh) * 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20140315295A1 (en) * 2013-03-15 2014-10-23 Creatv Microtech, Inc. Polymer microfilters, devices comprising the same, methods of manufacturing the same, and uses thereof
AU2012340576A1 (en) 2011-11-21 2015-04-30 Creatv Microtech, Inc. Polymer microfiltration devices, methods of manufacturing the same and the uses of the microfiltration devices
EP3400996B1 (de) 2012-06-01 2022-05-18 Creatv Microtech, Inc. Erfassung, identifizierung und verwendung neuer biomarker für feste tumore in körperflüssigkeiten
CA2959072C (en) * 2014-08-25 2025-12-09 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
JP7018885B2 (ja) * 2015-12-31 2022-02-14 プロガストリン、エ、カンセル、エス、アー エル、エル 食道癌の検出および治療のための組成物および方法
ES3014978T3 (en) 2016-04-14 2025-04-28 Creatv Microtech Inc Methods of using pd-l1 expression in treatment decisions for cancer therapy
KR102623286B1 (ko) 2017-02-16 2024-01-10 크리에티브이 마이크로테크, 인크. 순환성 암 관련 대식세포 유사 세포(camls)를 이용하여 암에 걸린 개체에서 전체 생존 및 무진행 생존을 예측하는 방법
EP3602051A1 (de) * 2017-03-31 2020-02-05 Creatv Microtech, Inc. Verfahren zur verwendung von riesenzellnukleinsäurecharakterisierung in krebsscreening, diagnostik, behandlung und rezidiv

Also Published As

Publication number Publication date
EP3765853B1 (de) 2024-05-01
JP2021517241A (ja) 2021-07-15
JP7692075B2 (ja) 2025-06-12
WO2019178226A1 (en) 2019-09-19
KR102834526B1 (ko) 2025-07-16
CA3093053A1 (en) 2019-09-19
JP7449640B2 (ja) 2024-03-14
EP3765853A1 (de) 2021-01-20
US20210041445A1 (en) 2021-02-11
CN112074742A (zh) 2020-12-11
AU2019235771B2 (en) 2025-03-13
KR20200131837A (ko) 2020-11-24
ES2980135T3 (es) 2024-09-30
AU2019235771A1 (en) 2020-09-24
JP2024063157A (ja) 2024-05-10

Similar Documents

Publication Publication Date Title
EP3765853C0 (de) Verfahren zur überwachung der behandlungsreaktion und des krankheitsverlaufs in subjekten unter verwendung zirkulierender zellen
EP3186397C0 (de) Verwendung von biomarkern zirkulierender zellen im blut zum nachweis und zur diagnose von krankheiten und verfahren zur isolierung davon
PL3413708T3 (pl) System i sposób do rejestracji i monitorowania zdrowia i rozwoju żywych ryb
EP3397139C0 (de) Vorrichtung, system und verfahren für nichtinvasiven überwachung von physiologischen messungen
EP3468356A4 (de) Genetisch modifizierte zellen, gewebe und organe zur behandlung von krankheiten
EP4123032C0 (de) Nachweis und behandlung von krankheiten mit krankheitszellheterogenität und systeme und verfahren zur kommunikation von testergebnissen
PT3559976T (pt) Método e aparelho para tratamento seletivo de tecido biológico
EP3585151A4 (de) System zur überwachung der tiergesundheit und verfahren zur verwendung
EP3359171C0 (de) Verwendung von akkermansia muciniphila zur behandlung von entzündlichen erkrankungen
EP3557984A4 (de) Tiergesundheitssystem und verfahren zur leistungsüberwachung
EP3285655A4 (de) Verfahren und system zur gewinnung von biologischem gewebe
EP3551033A4 (de) Endoskop und verfahren zur verwendung
EP3834710C0 (de) System und verfahren zur gesundheitsüberwachung unter verwendung eines nichtinvasiven mehrbandbiosensors
EP3448258C0 (de) Multiplextes transdermale extraktions- und detektionssystem zur nichtinvasiven überwachung von substanzen und verfahren zur verwendung
EP3450540A4 (de) Vorrichtung zur kultivierung von nervenzellen, verfahren zur kultivierung von nervenzellen, kultivierte nervenzelle, verfahren zur analyse und identifizierung von protein in axonbündel und verfahren zur verwendung der nervenzelle
EP3784232C0 (de) Verbesserte verfahren zur induzierung der geweberegeneration und der senolyse bei säugetierzellen
EP3445265A4 (de) Hautbehandlungsvorrichtung und -verfahren
EP3451914A4 (de) System und verfahren zur verwendung bei der gewebeüberwachung und -analyse
EP3463095C0 (de) Messanordnung zum überwachen von bestimmten aktivitätsparametern des menschlichen herzes
EP3489351A4 (de) Zellkultivierungsverfahren, suspendiertes zelleliminierungsverfahren und verfahren zum abtöten suspendierter zellen
EP3558327A4 (de) Gerüste zur behandlung von zellen solider tumoren und escape-varianten
EP2967329C0 (de) Vorrichtung zur verwendung in der diagnose von haut und kopfhaut, und verfahren unter verwendung der vorrichtung
EP3674710A4 (de) Zusammensetzung zur vorhersage oder diagnose von lebererkrankungen und lebererkrankungsvorhersage- oder -diagnoseverfahren unter verwendung davon
EP3516080A4 (de) Konstrukte zur kontinuierlichen überwachung von lebenden zellen
EP3347492A4 (de) Verfahren zur histologischen diagnose und behandlung von erkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20231117

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019051338

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20240523

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240621

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2980135

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240801

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240901

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240802

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019051338

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20250204

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 7

Effective date: 20250325

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250416

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250401

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260401

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260324

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20260323

Year of fee payment: 8